AbbVie Launches Skyrizi
2026-11-18 01:30:30

AbbVie Launches New 55mg Pre-filled Syringe for Skyrizi, Expanding Treatment for Pediatric Psoriasis

AbbVie Launches Skyrizi 55mg Pre-filled Syringe



AbbVie Inc., headquartered in Minato, Tokyo, has officially launched a new 55mg pre-filled syringe formulation of its monoclonal antibody drug, Skyrizi (risankizumab), on November 18, 2026. This launch represents a significant development in treating pediatric patients aged six and older who suffer from psoriasis, arthritis, and other associated conditions. With this new formulation, the drug is now applicable to pediatric patients who weigh less than 40kg, providing a much-needed treatment option for this demographic.

The acquisition of additional approval for this new formulation on September 16, 2026, follows the successful use of Skyrizi in treating moderate to severe psoriasis in adults, which began with its initial approval in March 2019. The efficacy of Skyrizi against conditions such as psoriatic arthritis and generalized pustular psoriasis has been recognized, and now pediatric patients can benefit from the same effective treatment.

Psoriasis is a chronic inflammatory skin disease characterized by red, raised patches covered with silvery scales. It affects approximately 430,000 individuals in Japan, with the prevalence being 0.8% in children aged 0-9 years and 1.8% in those aged 10-19. Given the visibility of psoriasis symptoms, patients often experience psychological challenges linked to body image and stigma, impacting their overall quality of life—especially among children who face social and academic hurdles.

Moreover, psoriasis in children is frequently associated with comorbid conditions such as obesity, dyslipidemia, hypertension, diabetes, and Crohn's disease. Studies have also linked psoriasis to increased risks for mental health conditions like depression and anxiety, highlighting the need for effective treatments that can improve both physical and mental well-being.

AbbVie anticipates that the introduction of the Skyrizi 55mg pre-filled syringe will support pediatric patients weighing less than 40kg in reaching their treatment goals for moderate to severe psoriasis, enhancing their quality of life.

Overview of Skyrizi (Risankizumab) 55mg Pre-filled Syringe


  • - Product Name: Skyrizi(R) Subcutaneous 55mg Syringe 0.37mL
  • - Generic Name: Risankizumab (Recombinant)
  • - Indications: To treat conditions where existing therapies have proven inadequate:
- Plaque psoriasis
- Psoriatic arthritis
- Generalized pustular psoriasis
- Erythrodermic psoriasis
  • - Dosage: For patients aged six and older—those weighing 40kg and above will receive 150mg per injection, while those under 40kg will receive 55mg. The treatment is administered subcutaneously at initiation, followed by administration every four weeks and subsequently every 12 weeks.
  • - Manufacturing and Sales Approval Date: September 16, 2026
  • - Price Listing Date: November 13, 2026
  • - Launch Date: November 18, 2026

About Skyrizi


Skyrizi is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23) and selectively inhibits its action. Beyond its initial indications, Skyrizi has also gained approval in Japan for treating various other conditions, including Crohn's disease and pustular psoriasis in adults, further expanding its application.

AbbVie is committed to innovative drug development to address severe health issues, focusing on immune-mediated diseases, oncological challenges, and the domains of mental health. For more information regarding AbbVie and its innovative treatments, please visit AbbVie. This dedication to improving the lives of patients ensures that AbbVie remains a leader in the pharmaceutical sector by continuously tackling pressing health challenges and bringing forward comprehensive treatment solutions.

Conclusion


As AbbVie continues to advance its mission in the field of dermatology, the launch of the Skyrizi 55mg pre-filled syringe is a crucial step in making effective therapies available to the pediatric population—a demographic that had limited treatment options until now. This forward-thinking approach not only promises to alleviate the physical symptoms associated with psoriasis but also aims to enhance the overall well-being of young patients navigating social challenges related to their condition.


画像1

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.